JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$3.21B |
| 2 |
Arthur J. Gallagher & Co
AJG
|
+$2.24B |
| 3 |
Walt Disney
DIS
|
+$2.18B |
| 4 |
Walmart Inc
WMT
|
+$1.96B |
| 5 |
McDonald's
MCD
|
+$1.91B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$2.77B |
| 2 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$2.64B |
| 3 |
Vanguard Long-Term Treasury ETF
VGLT
|
+$2.5B |
| 4 |
iShares Broad USD High Yield Corporate Bond ETF
USHY
|
+$2.23B |
| 5 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$2.06B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 24.61% |
| 2 | Technology | 23.17% |
| 3 | Financials | 10.12% |
| 4 | Consumer Discretionary | 9.84% |
| 5 | Healthcare | 7.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2276
ANI Pharmaceuticals
ANIP
$1.67B
| $14.8M | ﹤0.01% |
268,050
-286,785
| -52% | -$16.5M |
2016 Q1
35 quarters
|
|
2277
Rhythm Pharmaceuticals
RYTM
$6.24B
| $14.8M | ﹤0.01% |
264,585
+182,993
| +224% | +$10.1M |
2017 Q4
28 quarters
|
|
|
GRFS
2278
Grifois
GRFS
$5.02B
| $14.8M | ﹤0.01% |
1,988,043
-14,468
| -0.7% | -$121K |
2013 Q2
46 quarters
|
|
2279
iShares ESG Advanced Universal USD Bond ETF
EUSB
$691M
| $14.8M | ﹤0.01% |
347,847
-17,808
| -5% | -$769K |
2023 Q3
5 quarters
|
|
2280
Schwab US Mid-Cap ETF
SCHM
$14.7B
| $14.8M | ﹤0.01% |
533,200
-26,372
| -5% | -$751K |
2022 Q3
9 quarters
|
|
|
B
2281
PUT
Barrick Mining
B
$65.7B
| $14.8M | ﹤0.01% |
951,800
+674,800
| +244% | +$12.3M |
2023 Q1
7 quarters
|
|
2282
FNB Corp
FNB
$6.24B
| $14.7M | ﹤0.01% |
996,865
+9,781
| +1% | +$150K |
2013 Q2
46 quarters
|
|
2283
Vanguard Energy ETF
VDE
$10.8B
| $14.7M | ﹤0.01% |
121,435
-2,046
| -2% | -$261K |
2015 Q3
37 quarters
|
|
2284
Treace Medical Concepts
TMCI
$291M
| $14.7M | ﹤0.01% |
1,977,219
+714,984
| +57% | +$4.78M |
2021 Q2
14 quarters
|
|
2285
Sumitomo Mitsui Financial Group, Inc American Depositary Shares (each representing 1.2 shares of Common Stock)
SMFG
$163B
| $14.7M | ﹤0.01% |
1,015,206
-354,744
| -26% | -$4.87M |
2013 Q2
46 quarters
|
|
2286
Dimensional US Small Cap ETF
DFAS
$15.2B
| $14.7M | ﹤0.01% |
225,839
+31,889
| +16% | +$2.13M |
2022 Q4
8 quarters
|
|
|
AKRO
2287
DELISTED
Akero Therapeutics
AKRO
| $14.7M | ﹤0.01% |
528,207
+40,161
| +8% | +$1.22M |
2019 Q3
21 quarters
|
|
2288
Amer Sports
AS
$15.9B
| $14.7M | ﹤0.01% |
524,072
+522,512
| +33,494% | +$11.5M |
2024 Q3
1 quarter
|
|
2289
Hilltop Holdings
HTH
$2.2B
| $14.6M | ﹤0.01% |
511,418
+30,861
| +6% | +$964K |
2013 Q2
46 quarters
|
|
2290
PUT
Rivian
RIVN
$20.9B
| $14.6M | ﹤0.01% |
1,100,300
+893,000
| +431% | +$10.3M |
2023 Q3
5 quarters
|
|
2291
Hannon Armstrong Sustainable Infrastructure Capital
HASI
$4.66B
| $14.6M | ﹤0.01% |
544,699
+244,112
| +81% | +$7.63M |
2017 Q1
31 quarters
|
|
2292
Dimensional US Core Equity Market ETF
DFAU
$13B
| $14.6M | ﹤0.01% |
360,580
+16,471
| +5% | +$673K |
2022 Q4
8 quarters
|
|
2293
International Seaways
INSW
$5.79B
| $14.6M | ﹤0.01% |
406,197
+10,142
| +3% | +$432K |
2016 Q4
32 quarters
|
|
|
BNY
2294
CALL
Bank of New York Mellon
BNY
$97.6B
| $14.6M | ﹤0.01% |
190,000
| – | – |
2024 Q3
1 quarter
|
|
2295
PUT
Twilio
TWLO
$44.9B
| $14.6M | ﹤0.01% |
135,000
+95,000
| +238% | +$8.68M |
2024 Q2
2 quarters
|
|
2296
Vontier
VNT
$4.3B
| $14.6M | ﹤0.01% |
399,334
-14,503
| -4% | -$535K |
2020 Q4
16 quarters
|
|
2297
Ionis Pharmaceuticals
IONS
$7.27B
| $14.5M | ﹤0.01% |
415,919
-152,987
| -27% | -$5.72M |
2013 Q2
46 quarters
|
|
2298
Progress Software
PRGS
$1.51B
| $14.5M | ﹤0.01% |
222,891
-294,689
| -57% | -$19.7M |
2013 Q2
46 quarters
|
|
2299
iShares 10+ Year Investment Grade Corporate Bond ETF
IGLB
$2.51B
| $14.5M | ﹤0.01% |
293,909
-233,869
| -44% | -$12M |
2019 Q2
22 quarters
|
|
2300
CALL
US Bancorp Series B Preferred Stock
USB.PRH
$731M
| $14.5M | ﹤0.01% |
302,700
+301,700
| +30,170% | +$6.71M |
2024 Q3
1 quarter
|
|
Similar funds
JP Morgan Chase's Q4 2024 Portfolio in Review
As of Q4 2024, JP Morgan Chase held 7,917 positions worth $1.34T, up 2.1% from $1.32T the previous quarter. Its ten largest holdings account for 24% of the portfolio.
JP Morgan Chase's Q4 2024 filing shows 509 new, 3,351 increased, 2,465 reduced and 522 closed positions. Its largest new stake was Primo Brands: 3,989,501 shares worth $123M. The largest sale was Eli Lilly, an estimated $2.77B.
By sector, the portfolio is most concentrated in Miscellaneous at 25% of assets, up from 24% a quarter earlier, followed by Technology and Financials.
- JP Morgan Chase's largest Q4 2024 buy was Primo Brands: 3,989,501 shares worth $123M.
- JP Morgan Chase added most to Broadcom in Q4 2024, an estimated $3.21B increase.
- JP Morgan Chase's biggest Q4 2024 reduction was Eli Lilly, cutting an estimated $2.77B.
- JP Morgan Chase fully exited Stericycle Inc in Q4 2024, selling an estimated $183M.
- JP Morgan Chase's ten largest holdings make up 24% of its $1.34T portfolio in Q4 2024.
- JP Morgan Chase opened 509 new positions and closed 522 in Q4 2024.
- JP Morgan Chase's portfolio value rose 2.1% quarter-over-quarter to $1.34T.
Based on JP Morgan Chase's 13F filing for Q4 2024, filed 12 Feb 2025.